StreetAlpha.app
Home › Stocks › JANX

Janux Therapeutics, Inc. (JANX)

Healthcare
$10.08
▼ −2.04%
LAST CLOSE · NOV 20

Janux Therapeutics develops immunotherapy drugs that direct the immune system's T cells to attack tumors and autoimmune disease. It last closed at $10.08 on Nov 20, down 2.04% on the day. The next earnings report for JANX is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, JANX reported EPS of -$0.34 on revenue of $9.3M, with revenue down 7.1% from a year ago. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months JANX insiders bought $0 of stock on the open market and sold $457K, according to SEC Form 4 filings.

AI Auto Pilots
Is JANX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold JANX.

Key Stats

Last 12 months
Results
Revenue
$23.3M
+132.9% vs a year ago
Net income
−$99.8M
−428.7% margin
EPS (diluted)
−$1.59
Free cash flow
−$54.2M
−232.6% margin
Valuation
Market cap
$616.7M
61.2M shares
P/E
–
No P/E while losing money
Price to sales
26.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.8M
At Sep 30
Shareholder equity
$911.6M
Shares outstanding
61.2M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.6M$3.6MFY2021FY2022: $8.6M$8.6MFY2022FY2023: $8.1M$8.1MFY2023FY2024: $10.6M$10.6MFY2024FY2025: $10.0M$10.0MFY2025

From JANX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.34
Quarter ended Sep 2026
Year ago EPS
-$0.39
Same quarter last year
Revenue
$9.3M
−7.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.35Dec '24Mar 2025: -$0.38Mar '25Jun 2025: -$0.55Jun '25Sep 2025: -$0.39Sep '25Dec 2025: -$0.51Dec '25Mar 2026: -$0.39Mar '26Jun 2026: -$0.35Jun '26Sep 2026: -$0.34Sep '26Latest -$0.34
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $10.0MSep '25Dec 2025: $0Dec '25Mar 2026: $3.7MMar '26Jun 2026: $10.3MJun '26Sep 2026: $9.3MSep '26Latest $9.3M
How JANX moved after its last 8 reports
Average move the session after a report ±3.7%
Nov 5, 2026After the close+9.8%
Aug 6, 2026After the close−1.6%
May 7, 2026After the close−2.5%
Feb 26, 2026After the close−1.4%
Nov 6, 2025After the close−7.6%
Aug 7, 2025After the close+1.1%
May 8, 2025After the close−3.1%
Feb 27, 2025After the close+2.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on JANXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on JANX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on JANX

Technical Analysis

JANX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 42% below its 20 day and 58% below its 50 day average. It is 52% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $10.05, and the nearest resistance the Pivot at $10.22.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.7%/day
Key levels
$35.3452 week high+250.6%
$16.41100 day average+62.8%
$15.9650 day average+58.3%
$15.28200 day average+51.6%
$14.3420 day average+42.3%
$14.03Swing high (Jun 10)+39.2%
$10.40Pivot R1+3.2%
$10.22Pivot+1.4%
$10.08Last close
$10.0552 week low−0.3%
$9.91Pivot S1−1.7%
Indicators
RSI (14)25.32Oversold below 30Oversold
MACD-1.88Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)35.7Trending down
Williams %R-99.6Oversold below −80, overbought above −20Oversold
CCI (20)-94.2Oversold below −100, overbought above 100Neutral
Rate of change−42.8%Change over 10 sessionsBearish
ATR (14)$0.97Typical daily range, 9.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for JANX

What happened before

See how JANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow JANX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How JANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for JANXHow many large options trades hit JANX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

JANX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲124 buying vs 78 selling
  • ●Held by funds -0.3 pts
  • ▲Funds holding +5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding204199+2.5%
In funds' top 10110.0%
Held by funds100.4%100.7%−0.3 pts
New / increased32 / 9238 / 84+1.6%
Reduced / sold out51 / 2746 / 31+1.3%
Put/call ratio0.720.23+209.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See JANX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

JANX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$457K9 sales · 7 insiders
24% of the selling was under pre-arranged trading plans.
2025-12 sold $110K2026-01 sold $261K2026-05 sold $29K2026-06 sold $57KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 2Janeen Noel DoyleChief Corp. & Bus. Dev. OfcrSale4,059$14.03$57K
May 11Maria DobekVice President, AccountingSale2,038$14.17$29K
Jan 2David Alan CampbellPresident and CEOSale8,072$13.73$111K
Jan 2Andrew Hollman MeyerChief Business OfficerSale1,879$13.73$26K
Jan 2Charles M. WinterChief Technical OfficerSale2,401$13.73$33K
Jan 2Thomas DiRaimondoChief Scientific OfficerSale2,505$13.73$34K
Every insider buy and sale for JANX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See JANX insider trades →

From SEC Form 4 filings by JANX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JANX is in one of them and how their past JANX trades turned out.

JANX in the AI portfolios
Loading…

JANX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JANX in an article yet. Here's the latest on the wider market.

JANX in the news

About Janux Therapeutics

Janux Therapeutics is a biopharmaceutical company based in San Diego, California. It develops immunotherapy drugs that direct the body's T cells to attack tumors, and it is also developing treatments for autoimmune diseases. Its lead candidates are in clinical trials for prostate cancer and other solid tumors. The company's drug candidates are aimed at cancer patients and people living with autoimmune conditions.

Headquarters
San Diego, CA